Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity

Lisa Stevens; Kelly E Perry; Iakuna Moide; Francil Kaemala; Justine Nankinga; Anh L Innes; Ignatius Mogaba

doi:10.9745/GHSP-D-21-00595

Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity

Glob Health Sci Pract. 2022 Apr 29;10(2):e2100595. doi: 10.9745/GHSP-D-21-00595. Print 2022 Apr 28.

Authors

Lisa Stevens¹, Kelly E Perry², Iakuna Moide³, Francil Kaemala³, Justine Nankinga³, Anh L Innes⁴, Ignatius Mogaba³

Affiliations

¹ FHI 360 Asia Pacific Regional Office, Bangkok, Thailand. lstevens@fhi360.org.
² FHI 360 Asia Pacific Regional Office, Bangkok, Thailand.
³ FHI 360 Papua New Guinea Office, Port Moresby, Papua New Guinea.
⁴ FHI 360 Vietnam Office, Hanoi, Vietnam.

Abstract

Systems established for active drug safety monitoring and management of drug-resistant TB should be leveraged to ensure comprehensive surveillance for active toxicity monitoring during scale-up of newer antiretroviral regimens.

MeSH terms

Anti-HIV Agents* / adverse effects
Anti-Retroviral Agents / adverse effects
HIV Infections* / drug therapy
Humans

Substances

Anti-HIV Agents
Anti-Retroviral Agents